

## Pharmaceutical Policies Updates Effective October 1, 2022

To keep our valued care delivery partners up to date, MVP Health Care® (MVP) is sharing Pharmaceutical Policies updates effective October 1, 2022.

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at [mvphealthcare.com](http://mvphealthcare.com) and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective October 1, 2022 and will be available for viewing on or before September 1, 2022. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists	Updated
PCSK9 Inhibitors	Updated
Epinephrine Autoinjector	Reviewed/No Changes
Pulmonary Hypertension (Advanced Agents) Commercial	Reviewed/No Changes
Pulmonary Hypertension (Advanced Agents) Medicaid/HARP	Reviewed/No Changes
Migraine Agents- effective 9/1/2022	Updated
Transthyretin Mediated Amyloidosis Therapy	Reviewed/No Changes
Gout Treatments	Updated
ACL Inhibitors	Reviewed/No Changes
Methotrexate Autoinjector	Reviewed/No Changes
Cialis for BPH	Reviewed/No Changes
Orphan Drugs and Biologicals	Updated
Specialty Procurement (Commercial, Exchange & Select ASO business only)	Updated
Preventive Services-Medication effective 8/1/2022	Updated

To view all communications, visit [mvphealthcare.com/FastFax](http://mvphealthcare.com/FastFax)

**Questions?** Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

